Richard D. Kim, Anwaar Saeed, William J. Chapin, Kevin Kim, Renuka Iyer, Robert C.G. Martin, Axel Grothey, Saikrishna Gadde, Lynn G. Feun, Afshin Gabayan, Yvonne M. Saenger, Maen Abdelrahim, Nalini Govada, Ben Xie, May Cho, Adam Burgoyne. "A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.2_suppl.tps614